A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

NCT04186156 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study not progressing

Conditions

Biliary Tract Cancer

Interventions

DRUG: KA2507

Sponsor

Karus Therapeutics Limited

Collaborators

[object Object]